Unresectable or advanced recurrent HER2-positive gastric cancer or cardioesophageal cancer.
Conditions
Interventions
None listed
Sponsors
Hokkaido university hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have failed prior trastuzumab-based chemotherapy for unresectable advanced or recurrent gastric cancer. 2. Patients who have undergone (or will undergo) tissue collection (biopsy or surgery) and HER2 testing after completion of trastuzumab-containing chemotherapy. 3. Over 20 years of age. 4. Eastern Cooperative Oncology Group(ECOG) Performance Status(PS) 0-2. 5. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. Those with active multiple cancers. 2. Those who had drainage for fluid retention (pleural, ascites, pericardial fluid, etc.) within 2 weeks prior to enrollment. 3. Patients with pulmonary fibrosis or interstitial pneumonia. 4. Those with serious complications. 5. Those with active infectious diseases. 6. Those with active viral hepatitis. 7. Poorly controlled diabetes mellitus patients. 8. Those with serious psychiatric or central nervous system disorders. 9. Those with severely abnormal electrocardiogram or with clinically problematic cardiac condition. 10. Other individuals who are judged by the research director or co-researcher to be inappropriate as research subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival, Disease control rate, Overall survival, Safety, HER2 Status | — |
Countries
Japan
Contacts
Public ContactKoichi Ishida
Hokkaido University Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed